Olmeraas 20mg Tablet contains Ondansetron, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery. Ondansetron works by blocking serotonin receptors centrally in the chemoreceptor trigger zone and peripherally in the gastrointestinal tract, thereby inhibiting the emetic signals. Each tablet delivers 20mg of Ondansetron, providing an effective dose for adult patients requiring antiemetic therapy. Olmeraas is indicated for the management of acute and delayed nausea and vomiting induced by highly emetogenic cancer treatments and for preventing postoperative nausea and vomiting. The medication is generally well-tolerated, with common adverse effects including headache, constipation, and dizziness. It should be used with caution in patients with hepatic impairment and those with a history of cardiac arrhythmias, as Ondansetron may prolong the QT interval. Dosage adjustments may be necessary based on clinical response and patient condition. Olmeraas 20mg Tablet should be administered under medical supervision, with adherence to prescribed dosing schedules to optimize therapeutic outcomes and minimize potential side effects. It is contraindicated in patients with known hypersensitivity to Ondansetron or any of its components.